Abstract
The term dyskinesia was originally coined to design any form of hyperkinetic movement disorder emerging in the context of treatment with dopamine blocking agents, but it is a vague term and nowadays is prefer to define in the most precise manner the predominant phenomenology of the movement disorder. Splitting the concept of dyskinesia in this way will provide the clinician not only a solid classification scheme but also with optimised strategies in terms of treatment.
References
Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome) : Current concept and modern approaches to its management. Psychiatry and clinical neurosciences 2015; 69(6): 321-34.
Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgraduate medical journal 2011; 87(1024): 132-41.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC; 2013.
Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 81(5): 463-9.
Orti-Pareja M, Jimenez-Jimenez FJ, Vazquez A, et al. Drug-induced tardive syndromes. Parkinsonism & related disorders 1999; 5(1-2): 59-65.
Keegan DL, Rajput AH. Drug induced dystonia tarda: treatment with L-dopa. Diseases of the nervous system 1973; 34(3): 167-9.
Krack P, Schneider S, Deuschl G. Geste device in tardive dystonia with retrocollis and opisthotonic posturing. Movement disorders: official journal of the Movement Disorder Society 1998; 13(1): 155-7.
Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32(12): 1335-46.
Adityanjee, Aderibigbe YA, Jampala VC, Mathews T. The current status of tardive dystonia. Biological psychiatry 1999; 45(6): 715-30.
Sethi KD. Drug-Induced Movement Disorders. 1 ed: CRC Press; 2004.
Ryu S, Yoo JH, Kim JH, et al. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. Journal of clinical psychopharmacology 2015; 35(1): 13-21.
Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain: a journal of neurology 1998; 121 ( Pt 11): 2053-66.
Casey DE. Tardive dyskinesia: pathophysiology and animal models. The Journal of clinical psychiatry 2000; 61 Suppl 4: 5-9.
Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor and other hyperkinetic movements 2013; 3.
Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. The American journal of psychiatry 1999; 156(8): 1200-4.
Skidmore F, Reich SG. Tardive Dystonia. Current treatment options in neurology 2005; 7(3): 231-6.
Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs 2016; 76(7): 779-87.
Pinninti NR, Faden J, Adityanjee A. Are Second-Generation Antipsychotics Useful in Tardive Dystonia? Clinical neuropharmacology 2015; 38(5): 183-97.
Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Movement disorders: official journal of the Movement Disorder Society 1986; 1(3): 193-208.
Sobstyl M, Zabek M. Deep brain stimulation for intractable tar-dive dystonia: Literature overview. Neurologia i neurochirurgia polska 2016; 50(2): 114-22.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.